Back to search

Article

Apremilast reverses the profibrotic phenotype of dermal fibroblasts derived from patients with systemic sclerosis and prevents the progression of bleomycin-induced dermal fibrosis in mice

2023-03-02

Abstract excerpt

Phosphodiesterase (PDE) 4 inhibitors have been reported to suppress the progression of dermal fibrosis in patients with systemic sclerosis (SSc); however, the precise mechanisms remain to be elucidated. Therefore, we conducted experiments focusing on the antifibrotic and anti-inflammatory effects of apremilast using dermal fibroblasts derived from patients with SSc and an SSc mouse model. Dermal fibroblasts derive...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6d8abfd0-2785-57ec-8c7e-7e15e765bb86
DOI
10.21203/rs.3.rs-2610128/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Apremilast reverses the profibrotic phenotype of dermal fibroblasts derived from patients with systemic sclerosis and prevents the progression of bleomycin-induced dermal fibrosis in miceDOI 10.21203/rs.3.rs-2610128/v1
Select a neighboring publication to make it the new centre.